Mesoporous Silicon‐PLGA Composite Microspheres for the Double Controlled Release of Biomolecules for Orthopedic Tissue Engineering

In this study, poly(dl-lactide-co-glycolide)/porous silicon (PLGA/pSi) composite microspheres, synthesized by a solid-in-oil-in-water (S/O/W) emulsion method, are developed for the long-term controlled delivery of biomolecules for orthopedic tissue engineering applications. Confocal and fluorescent microscopy, together with material analysis, show that each composite microsphere contained multiple pSi particles embedded within the PLGA matrix. The release profiles of fluorescein isothiocyanate (FITC)-labeled bovine serum albumin (FITC-BSA), loaded inside the pSi within the PLGA matrix, indicate that both PLGA and pSi contribute to the control of the release rate of the payload. Protein stability studies show that PLGA/pSi composite can protect BSA from degradation during the long term release. We find that during the degradation of the composite material, the presence of the pSi particles neutralizes the acidic pH due to the PLGA degradation by-products, thus minimizing the risk of inducing inflammatory responses in the exposed cells while stimulating the mineralization in osteogenic growth media. Confocal studies show that the cellular uptake of the composite microspheres is avoided, while the fluorescent payload is detectable intracellularly after 7 days of co-incubation. In conclusion, the PLGA/pSi composite microspheres offer an additional level of controlled release and could be ideal candidates as drug delivery vehicles for orthopedic tissue engineering applications.

[1]  Mauro Ferrari,et al.  Mitotic trafficking of silicon microparticles. , 2009, Nanoscale.

[2]  Mauro Ferrari,et al.  Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast , 2010, Nature nanotechnology.

[3]  Wim E. Hennink,et al.  Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles , 2000, Pharmaceutical Research.

[4]  J. Jansen,et al.  PLGA microsphere/calcium phosphate cement composites for tissue engineering: in vitro release and degradation characteristics , 2008, Journal of biomaterials science. Polymer edition.

[5]  M Ferrari,et al.  Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Peter W. Swaan,et al.  Microfabricated Porous Silicon Particles Enhance Paracellular Delivery of Insulin Across Intestinal Caco-2 Cell Monolayers , 2004, Pharmaceutical Research.

[7]  R. P. Thompson,et al.  Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. , 2003, Bone.

[8]  William G Telford,et al.  Dynamics and mechanisms of quantum dot nanoparticle cellular uptake , 2010, Journal of Nanobiotechnology.

[9]  C. Waters,et al.  Endocytosis of growth factor receptors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[10]  E. Fabrizio,et al.  Porous silicon as drug carrier for controlled delivery of doxorubicin anticancer agent , 2006 .

[11]  W. Skinner,et al.  Loading and release of a model protein from porous silicon powders , 2007 .

[12]  N. Voelcker,et al.  New biodegradable materials produced by ring opening polymerisation of poly(L-lactide) on porous silicon substrates. , 2009, Journal of colloid and interface science.

[13]  C. Bucana,et al.  Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. , 1981, Cancer research.

[14]  Dan Luo,et al.  Cellular Fate of a Modular DNA Delivery System Mediated by Silica Nanoparticles , 2008, Biotechnology progress.

[15]  J. Eisinger,et al.  Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study. , 1993, Magnesium research.

[16]  J. Salonen,et al.  Mesoporous silicon in drug delivery applications. , 2008, Journal of pharmaceutical sciences.

[17]  H. Gavras,et al.  Cell Signaling, Internalization, and Nuclear Localization of the Angiotensin Converting Enzyme in Smooth Muscle and Endothelial Cells* , 2009, The Journal of Biological Chemistry.

[18]  H. M. Nielsen,et al.  Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation , 2009, Journal of Controlled Release.

[19]  L. Canham,et al.  The role of nanostructured mesoporous silicon in discriminating in vitro calcification for electrospun composite tissue engineering scaffolds. , 2011, Nanoscale.

[20]  Samir Mitragotri,et al.  Polymer particle shape independently influences binding and internalization by macrophages. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[21]  P. Chow,et al.  A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device--a first-in-man study. , 2007, International journal of radiation oncology, biology, physics.

[22]  M. Schwab,et al.  Nerve growth factor-mediated induction of choline acetyltransferase in PC12 cells: evaluation of the site of action of nerve growth factor and the involvement of lysosomal degradation products of nerve growth factor , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  H. Gu,et al.  Study on the endocytosis and the internalization mechanism of aminosilane-coated Fe3O4 nanoparticles in vitro , 2007, Journal of materials science. Materials in medicine.

[24]  I. Pastan,et al.  Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Mauro Ferrari,et al.  Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.

[26]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[27]  L. Canham Nanoscale semiconducting silicon as a nutritional food additive , 2007 .

[28]  S. C. Bayliss,et al.  Biologically Interfaced Porous Silicon Devices , 2000 .

[29]  M Ferrari,et al.  Acute Toxicity of Intravenously Administered Microfabricated Silicon Dioxide Drug Delivery Particles in Mice , 2005, Drugs in R&D.

[30]  Mauro Ferrari,et al.  Tailored porous silicon microparticles: fabrication and properties. , 2010, Chemphyschem : a European journal of chemical physics and physical chemistry.

[31]  L. Canham Bioactive silicon structure fabrication through nanoetching techniques , 1995 .

[32]  Steven J P McInnes,et al.  Silicon-polymer hybrid materials for drug delivery. , 2009, Future medicinal chemistry.

[33]  Priyabrata Mukherjee,et al.  Biorelevant mesoporous silicon / polymer composites: directed assembly, disassembly, and controlled release , 2006, Biomedical microdevices.

[34]  Priyabrata Mukherjee,et al.  High-porosity poly(epsilon-caprolactone)/mesoporous silicon scaffolds: calcium phosphate deposition and biological response to bone precursor cells. , 2008, Tissue engineering. Part A.

[35]  Priyabrata Mukherjee,et al.  Porous silicon‐based scaffolds for tissue engineering and other biomedical applications , 2005 .

[36]  G. Lu,et al.  Functionalized Mesoporous Silica with Very Large Pores for Cellulase Immobilization , 2010 .

[37]  Michael J Sailor,et al.  Biodegradable luminescent porous silicon nanoparticles for in vivo applications. , 2009, Nature materials.

[38]  Benjamin C. Tang,et al.  Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier , 2009, Proceedings of the National Academy of Sciences.

[39]  L. Canham,et al.  Accelerated calcification in electrically conductive polymer composites comprised of poly(epsilon-caprolactone), polyaniline, and bioactive mesoporous silicon. , 2007, Journal of biomedical materials research. Part A.

[40]  F. Morel,et al.  A Proton Buffering Role for Silica in Diatoms , 2002, Science.

[41]  C. Sousa,et al.  Phagocytosis of antigens by Langerhans cells in vitro , 1993, The Journal of experimental medicine.

[42]  M. Sailor,et al.  Engineering the chemistry and nanostructure of porous silicon Fabry-Pérot films for loading and release of a steroid. , 2004, Langmuir : the ACS journal of surfaces and colloids.

[43]  Robert Langer,et al.  PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. , 2009, Biomaterials.

[44]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[45]  A. Schilling,et al.  Biologically and chemically optimized composites of carbonated apatite and polyglycolide as bone substitution materials. , 2001, Journal of biomedical materials research.

[46]  Jong-Chul Park,et al.  PLGA scaffold incorporated with hydroxyapatite for cartilage regeneration , 2008 .

[47]  Mauro Ferrari,et al.  Near-Infrared Imaging Method for the In Vivo Assessment of the Biodistribution of Nanoporous Silicon Particles , 2011, Molecular imaging.

[48]  H. Herschman,et al.  Specific radiolabeling of a cell surface receptor for epidermal growth factor. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Ge Jiang,et al.  Preparation and Characterization of a Composite PLGA and Poly(Acryloyl Hydroxyethyl Starch) Microsphere System for Protein Delivery , 2001, Pharmaceutical Research.

[50]  Gwo‐Jaw Wang,et al.  Controlled release carrier of BSA made by W/O/W emulsion method containing PLGA and hydroxyapatite. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[51]  G. Carpenter,et al.  125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts , 1976, The Journal of cell biology.